Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cimlanod - Bristol-Myers Squibb

Drug Profile

Cimlanod - Bristol-Myers Squibb

Alternative Names: BMS-986231; BMS-986231-01; Cimlanod; CXL 1427; HNO Donor; HNO Nitroxyl Donor

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardioxyl Pharmaceuticals
  • Developer Bristol-Myers Squibb
  • Class Heart failure therapies; Sulfonamides
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Decompensated heart failure; Heart failure

Most Recent Events

  • 29 Aug 2019 Bristol-Myers Squibb completes a phase I in Decompensated heart failure Hungary and Poland (NCT03515980)
  • 29 Jul 2019 Bristol-Myers Squibb completes a phase I trial in Heart failure (In volunteers) in USA (IV) (NCT03891108)
  • 23 Jun 2019 Bristol-Myers Squibb completes phase II clinical trials in Decompensated heart failure in the US, the UK, Argentina, Canada, Czech Republic, France, Germany, Greece, Italy, Japan, the Netherlands, Poland and Spain (IV, Infusion) (NCT03016325)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top